Q1 2025 Charles River Laboratories International Inc Earnings Call
One more way maybe! No! It's not there! You have to take that B! The bees! I almost forgot! P cooperation! I'll have it ready! Thank you Produce-Bee! Now then, Forever being your appreciated friend, Goodbye!
Please stand by, your program is about to begin. Let's begin.
Speaker Change: Ladies and gentlemen, thank you for standing by, and welcome to the
This call is being recorded. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session.
Speaker Change: To answer to ask a question during this period, we'll make the press star one on the telephone. If you want to remove yourself from the queue, please press star two.
Lastly, should you need operator assistance? Please press star zero.
Speaker Change: I would now like to turn the conference over to your host, Todd Spencer, Vice President of Investigations. You may go ahead.
David Windley, Michael Ryskin, Michael Ryskin, Michael Ryskin, Michael Ryskin
Speaker Change: Good morning, and welcome to Charles River Laboratories' first quarter, 2025, at Her name's Todd Fist Hall and Web Chat.
Speaker Change: This morning I am joined by Jim Foster, Chair, President and Chief Executive Officer, and Flavia Pease, Executive Vice President and Chief Financial Officer.
Speaker Change: They will comment on our results for the first quarter of 2025. All of the presentations will respond to questions.
Speaker Change: There is a slide presentation associated with today's remarks, which will be posted on the next presentation section of our website at ir.tvr.com
Speaker Change: A replay of this call will be available to give you approximately two hours after the call today, and can also be accessed on our Investulations website.
Speaker Change: The replay will be available through the next quarter's conference.
I'd like to remind you of our State Farm Work.
Speaker Change: on the market to make about future expectations, plans, prospects for the company, constitute four of the constituents under the private securities organization reform act of 1995. Actual results made there for materially from those indicated.
Speaker Change: During this call, we will primarily discuss non-GAAP financial measures which we believe help investors gain meaningful understanding of our core operating results in guidance.
Speaker Change: The non-GAAP financial measures are not meant to be considered superior to or a substitute for results for operations prepared in accordance with the gap.
Speaker Change: In accordance with Regulation G, you can find out more about that measures and recommendations on the Investor Relations section of our website. Now turn the call over to Jim Foster.
Thanks for watching!
Jim Foster: Thank you, Todd, and thank you all for joining us today.
Jim Foster: Before discussing our first quarter results, I'd like to take a few minutes to directly address an important regulatory development. The FDA is announced in the last two months.
Jim Foster: with Outlining the Gold to Accelerate the Validation and Adoption of New Approach Methods for the first time in a year.
to reduce the animal testing in pre-clinical safety assessment. [inaudible]
Jim Foster: I will also talk about today on our own ongoing strategy for that alternative methods.
Jim Foster: which will continue to incorporate into our business in the future.
Speaker Change: Charles River supports the FDA's vision to leverage scientific advancement to safely advance innovative technologies.
including alternatives to animal views.
as the leader in pre-clinical drug development, our longstanding mission is to
to the line with the situation.
Speaker Change: As we continue to drive greater efficiency in the drug development process and reduce costs, enhance scientific innovation, and promote the responsible use of the animals and biomedical research. Our perspective on leading
Speaker Change: Inc. Annes, Enabled Futures, as follows. First, the evolution of NAMS is not known.
and demonstrate that scientific advancements are continuing to move forward.
Speaker Change: For more than 50 years, efforts to reduce animal use by Charles River and industry have led to a gradual decline in research model volumes.
Speaker Change: These efforts include educational, educational models, and technologies such as genetically modified educational and educational models that can mimic human disease. For example, our volumes of federal programs often used in safety assessment.
Speaker Change: have been roughly halved over the past 10 years due to the use of more complex
Model, Technology and Services.
Speaker Change: including imaging and individual applications, all while our revenue has increased significantly.
Speaker Change: Nans are part of this broader trend. For many years, heroes like Charles River, the biopharmaceutical industry, the FDA, and the International Regulatory Committee.
Speaker Change: have been evaluating strategies to use NAMS as tools to complement traditional NAMS. [inaudible]
and in some cases to potentially eliminate surveillance.
Speaker Change: Through this evolution, the promise of nabs will be balanced with the importance of patient safety and science.
Nance O'Brien,
offer exciting opportunities for the future.
Speaker Change: that are not capable of fully replacing animal studies and biomedical research and safety testing.
Speaker Change: Each NAMS tool will require a rigorous validation to prove that it can consistently replicate the complexity of living systems and ensure patient safety.
Speaker Change: There are applications where NAMS may play a valuable role more quickly.
Such as Martin Polo and Antibodies. [inaudible]
Speaker Change: Let significant scientific advancements and validation will be required before alternative methods can become more widely adopted. This technology to mimic a complex living organism doesn't exist today.
Therefore, we believe there will be incremental progress over time.
Speaker Change: and the broader adoption of the NANDs will be a part of the term journey.
One that is much longer than three to five years. [inaudible]
Speaker Change: The science continues to advance. We believe the biopharmaceutical industry and regulators will maintain a keen focus on ensuring patient safety without compromise [inaudible]
Speaker Change: As NANDs evolve, we intend to advance hybrid design by complementing traditional Indivo and digital methods with NANDs, and have been eyeing animal technologies.
Speaker Change: Given the current state of science and technology, NEMS are still primarily used in drug discovery because of the narrower focus on drug design and optimization.
Speaker Change: whereas in safety assessment and more comprehensive progress is required to determine the full of multi-organ impacts of the drug.
Speaker Change: Chronic or longer term assessments of a drug's impact are also critical, as well as off-target or unintended effects, which nams can't fully replicate at this time. However,
Speaker Change: We've got some applications in drug discovery. We believe a hybrid model, submitting nanostata in parallel with animal data, will prove to be the best approached
Speaker Change: Corporation Safety, full regulated safety test taking over the long term. Ultimately, we believe the future is binary. The use of the animals will remain beneficial to support certain complex safety at appropriate points, even as hybrid study designs.
Corporate Thought Nams and Animal Data Game Traction.
David Windley, Michael Ryskin, Michael Ryskin, Michael Ryskin, Michael Ryskin, Michael Ryskin,
Speaker Change: As a result, review this as an opportunity for Charles Ryskin
and we will continue to expand our non-animal platforms.
Speaker Change: that Patrick Dease is equally applicable to NAMS for which we have a growing portfolio of capabilities.
We will continue to invest heavily in these capabilities.
to Organic Innovation Technology Partnerships. [inaudible]
and David M&A.
Speaker Change: As regulatory expectations continue to evolve, our clients are trying to express their partners to help them navigate the transition.
Speaker Change: Charles River's homological partner to assist bioparticle clients to validate and advance the use of NAMS because of the scientific data that we've discussed in our regulatory expertise.
Speaker Change: Drug Development is ultimately about scientific data, and we have generated significant client database of toxicology information.
Speaker Change: over 25 years in the industry that can help create more predictive and efficient safety methodologies that do not compromise patient safety.
Charles River has a well established commitment.
Speaker Change: to interact with the people of the location, reduction, and refinement with the three hours of ethical animal use for biomedical research, and I supported the FDA's efforts as well as the NIH's to advance the validation and adoption of NAMS over many years.
Speaker Change: We have recognized this project to be assigned to technology for many years and in April 2024.
Speaker Change: We formalized our own alternative methods advanced in project or AMAP initiative.
dedicated to the development of alternatives to reducing animal testing.
we have made
Speaker Change: Investments of the past decade, in areas that are special to the NAMS ecosystem.
with growing capabilities that include seroid, organoid, and organone chip platforms.
Speaker Change: Human tissue models in silico modeling, advanced in vitro toxicology, and predictive immunotoxicology at <expletive> days.
It's also an investment in project using COD.
Speaker Change: Modeling to increase efficiency and reducing the usage as exemplified by a logical platform peering AI with traditional methods.
Speaker Change: We require the retrogenic cell microarray technology for off-target screening and toxicity.
Speaker Change: and we also launched a pilot program to replace the animals with virtual control groups for safety assessment studies.
Speaker Change: Slide 9 in our running presentation. Show cases that currently stay in there.
Speaker Change: and our capabilities across the various man's platforms. In total, we generated approximately $200 million dollars of annual D.S. Day revenue from men.
Much of which is in this category.
Speaker Change: We believe our nan's capabilities and associate revenue will grow meaningfully over time, as gradual technological progress continues.
Thank you for joining us.
Speaker Change: I'd like to take a moment to address the potential financial impact to Charles River from the FDA announcement.
Speaker Change: The FDA has focused on monoclonating the STRIP program specifically to reduce the duration of chronic
Speaker Change: We believe the FDA chose this path because in a case-by-case basis, it has already been waived in certain chronic post-IND NHP studies, monoclonal antibodies for many years using a way to prevent this model.
Speaker Change: because of the scientific data that has demonstrated that in many cases, there is limited to conducting additional product and HP studies.
Speaker Change: This is likely because monoclonal antibodies generally show less toxicity than small amounts of drugs and have a lower risk for unexpected reactions.
Speaker Change: In addition, certain monochrome antibodies have no problem with the research models to use in safety testing.
Speaker Change: Chronic MHP studies, longer than three months in monoclonal antibodies, represented 50 million dollars in total annual revenue. We do not expect any immediate impact on other things.
Speaker Change: On Slide 11, we have provided an updated review of our Safety Assessment Revenue by Drug Modality for reference. As you can see, the bulk of our revenue is from small molecule and newer advanced biological drugs, including cell and gene therapies.
Speaker Change: The FDA has not yet focused on these other drug modelities because understanding the safety profile
Speaker Change: can be more complex and less predictable than minor clone antibodies. And in the case of newer biologic drugs, there is also less data available to support non-animal-based risk assessments.
Speaker Change: Therefore, extensive validation work and scientific advancements are needed to safely complement the current and vivo protocols with new alternative methods.
Speaker Change: This will take a significant amount of time and require resources and collaboration between the FDA, NIH, and other agencies, as well as the biopharmaceutical industry.
We applaud the FDA's ongoing efforts to reduce animal use.
Foundation to Nancy's Evolutionary, rather than Revolutionary.
Speaker Change: It's an important one to buy another group of search, and one that Charles River is prepared to lead.
Speaker Change: In the coming years, we look forward to continuing to work with regulatory agencies, the biopharmaceutical industry in the state of coldness, to help develop, validate, and implement an efficient process for our clients' regulatory submissions.
for the use of nine animal technologies in new alternative methods.
As we host this event
Speaker Change: Charles River will remain committed to following the best and latest science to ensure patient safety.
Speaker Change: Now I'd like you to provide an update on the market trend.
Speaker Change: Despite considerable uncertainty in the broader market environment, our first quarter of the time has been resolved. Demonstrated continued time stabilization, with a better than expected DSA.
Speaker Change: Conference, leading us to modestly increase our financial guidance for the year.
Speaker Change: We were pleased to see the DSA network to build return to just about one time.
Speaker Change: for the first time in over two years due to improved boardwalking.
Speaker Change: While this is a positive development for the DSCA segment, we would be very cautious in light of recent market events.
including government funding cuts. [inaudible]
Speaker Change: particularly at the NIH and FDA, the slowest stocks of biotech funding and tariffs.
Speaker Change: Development have understandably contributed to a broader sense of uncertainty in the marketplace, while we have not yet seen a meaningful impact on clients' demands.
Speaker Change: which continues to show signs of stabilization, we have taken a measured and prudent approach to our outlook for the year.
Speaker Change: Highlights of our first quarter performance.
Speaker Change: $984.2 million in the first quarter of 2025, the 2.7% decrease compared to last year.
Speaker Change: on an organic basis, revenue declined 1.8%, driven by low single-digit organic decreases in each of our three business segments.
Speaker Change: Our first quarter revenue performance was above our February outlook for a mid-single-digit decline due primarily to the DSA's performance performance.
which I will provide more details shortly.
by client segment, revenue for small and mid-sized biopic clients.
Speaker Change: Group for a second consecutive quarter, revenue for global biopharmaceutical clients in the industrial squadron.
Speaker Change: But this was due at least a prior to the fact that we had an idea at anniversary of this sending reductions.
Speaker Change: which began in the second half of last year. Collectively, our global academic and government revenue increases significantly in the quarter.
Speaker Change: The operating margin was 19.1% and increased to 60 basis points year over year.
Speaker Change: The improvement was primarily driven by the benefit of cost savings.
Speaker Change: from a structured initiative that promoted margin expansion in the DSX segment.
Speaker Change: Federal will mix in the DSA segment, also distributive, as to the unallocated corporate cost.
who's declined year-over-year as expected.
Speaker Change: Thanks for sharing with 2034 cents in the first quarter, an increase of 300% from the first quarter of last year.
Speaker Change: in addition to operating margin improvement. Below the line items, including reductions in the tax rate, interest expense, and diluted shares of outstanding will contribute as to earning growth. Flavia will provide more details on this.
Thank you for joining us. Thank you.
Speaker Change: Bates primarily on the first quarter of the DSA on the performance and our current visibility balanced by a cautious approach to the second half of the year. We are modestly raising our 2025 revenue guidance by a hundred basis points.
Speaker Change: to a 2.5 to 4.5 percent decrease organically, and our nine gap earnings for sheer guidance by 20 cents at mid-point.
to $9.30 to $9.80.
Speaker Change: I'd now like to provide you with additional details on our first quarter segment performance, beginning with the DSA segment's results.
Speaker Change: The first quarter was $592.6 million, a decrease of 1.4% on an organic basis driven primarily by lower revenue for discovery services.
D.S. Day pricing improved slightly.
Speaker Change: in the first quarter. This was primarily driven by favorable necks.
Speaker Change: specifically an increase in long-deterredation specialty studies. We do not have to look at the city's broader improvement in the spot crisis environment, which we will continue to characterise as stable overall.
Moving to the DSA demand KPIs in slide 19.
Speaker Change: The DSA backlog was $1.99 billion at the end of the first quarter, slightly from $1.97 billion at year end.
Speaker Change: You should note that the beginning of this quarter, we have disclosed our net bookings and net bookings [inaudible]
Speaker Change: Bill Data. This is the first time we are providing this information because we believe it will provide additional transparency into these important KPIs.
Speaker Change: particularly when foreign exchange can have a notable impact on backlog as it did in the 404.
Speaker Change: As I mentioned earlier, we were pleased that the net book to be all improved to 1.04 times in the first quarter, above one time since the first time since the second half of 2022.
This is primarily a result of quarterly net booking.
Speaker Change: Activity, which improved to $660 million, representing more than 20% of the
and both the year-over-year and sequential basis.
The improvement was driven by higher growth bookings. [inaudible]
Speaker Change: currently from Global Biopharmaceutical Clients, as well as the continued decline in study cancellations, moving to point to top-rated levels across all kinds of things.
Inc. Small and Mid-Stice biotech. [inaudible]
Speaker Change: The instrumental for a squirt of booking activity could largely attract drivers studies with
which is more reflective of our current short-term booking behaviors
and the American Environment.
Speaker Change: We expect this will benefit revenue in the first half of this year, including the studies that were already started in the first quarter that led to the better than expected performance.
Speaker Change: Based on this trend, we are modestly increasing our full-year revenue guidance to the USA segment. We now expect the USA organic revenue will decline in the mid-single-digit range.
rather than a prior outlook of a mid-to-high single digit decline. [inaudible]
Speaker Change: As I mentioned, we expect the improved first quarter bookings will generate incremental revenue.
in the first half of the year, also augmented by it. [inaudible]
at the setting extra in the first quarter. [inaudible]
Speaker Change: At this point, given the current visibility, it generally cautious in the sector, in our expectation that the study of Maxwell normalizes
Speaker Change: We are not assuming that a similar bookings tailwind will continue to benefit second half revenue, however, as I said earlier, we have not seen any meaningful evidence of deterioration in our markets [inaudible]
Speaker Change: The DSA operating market increased 40 basis points year over year to 23.9% in the first quarter.
Speaker Change: The year-of-year improvement primarily reflected cost savings generated some of our re-struction initiatives as well as the study mix in the first quarter.
Speaker Change: RMS Revenue was 213.1 million dollars and decreased of 2.5% on an organic basis compared to the first
are most in line with expectations to start the year.
Speaker Change: The year-over-year revenue decline was primarily driven by the timing of NHP shipments in China.
Speaker Change: and another revenue for the self-solutions business. Partially, I've set the entire revenue for small research models in all geographic regions.
driven primarily by higher pricing. [inaudible]
Speaker Change: Small research models remain essential, low-cost tools for biomedical research, which enhances
for that price increases. [inaudible]
Thank you.
Speaker Change: However, there has been growing concerns from our academic and government clients that have proposed an NIH budget cut, and a certainty in Washington could impact the future.
Speaker Change: We have not experienced any meaningful revenue loss related to NIH budgets.
Speaker Change: and first quarter revenue from our North American government client increased slightly.
Speaker Change: As a reminder, this North American client base represents just over 20% of total RMS revenue or approximately 6% of total company revenue.
Speaker Change: and any potential NIH budget cuts would be unlikely to impact client spending levels until the latest or into 2026.
Speaker Change: In addition, the man from the local state biotech climate for our cradle services is expected to be constrained this year due to their funding challenges.
Speaker Change: We believe this will slow the anticipated utilization of cradle capacity during the year.
as a result of these two potential headwinds. [inaudible]
Speaker Change: We are moderating our RMSL for the year to flat the slightly positive evidence growth on an organic
compared to a previous explanation of low single digit growth.
Speaker Change: In the first quarter, the RMS operating margin decreased by 50 basis points to 27.1 percent.
Speaker Change: The decline was primarily a result of the lower NHP revenue, partially offset by the benefit of cost savings.
resulted from my Restructuring Initiative.
Speaker Change: Revenue for the Manufacturing Segment was $178.5 million, a 2.2% decrease on an annual pandemic basis from the first quarter of last year.
The Revenue Decline
primarily by lowest commercial revenue in the CDMO business.
Speaker Change: and a slow start of the year for the Biologics Festival.
Speaker Change: Overall, the manufacturing segments started the year in line with their expectations. [inaudible]
Speaker Change: and we are maintaining our prior outlook and manufacturing revenue will be essentially slapped on an organic basis in 2025.
As you know, first quarter testing, testing volumes. [inaudible]
Speaker Change: Dialogic Catching Business. It fluctuates based on seasonal trends.
The business had a stronger start last year.
Speaker Change: However, we continue to expect a biologic testing revenue.
Speaker Change: 1525, and this outlook was supported by solid booking activity in the first place.
Speaker Change: Our cell and gene therapy CDMO business was impacted by the lower revenue from two commercial
which we discussed earlier in the year.
Speaker Change: The loss of commercial CDMO revenue reduced the manufacturing solution by approximately 500 basis points in the first quarter, and is expected to have a similar intact for the community.
Speaker Change: We are continuing to make progress to enhance the quality of our CDMO operation.
We were also...
Speaker Change: to see that I've jean therapy, CDML rather than ruin the poor. [inaudible]
Speaker Change: We have a healthy pipeline of IoT clients with early stage clinical candidates ready to help move the CDMO business forward.
and continue to believe attractive long-term growth opportunity to trust.
Ostering East Headwinds
and Microbial Solutions Business.
Speaker Change: reported another quarter of solid growth across its existing portfolio, the rapid manufacturing quality control test solutions.
by Acogenics, Microbial Identification Services.
Anderson.
Speaker Change: as a result of both the testing and consumables, a strong high throughput automated nexus instrument placements last year are driving incremental cartridge demand.
Speaker Change: We expect my closing submissions will remain a stable source of high single-digit revenue growth.
Thank you.
Speaker Change: Demonstrating that clients are increasingly utilizing our comprehensive testing solutions to enhance their product release testing speed and efficiency.
Speaker Change: The manufacturing segments operating large and declined by 220 basis points, 23.1% in the first quarter of 2025, do principally
Speaker Change: to the impact of lower commercial revenue in the CDMO business. We believe the manufacturing segments margin will rebound to sales volume improves.
Particularly in the biologist testing business.
Speaker Change: and will move closer to the 30% level during the year.
Before I turn it over to Flavia,
Speaker Change: I would also like to discuss this morning's announcement regarding our
Speaker Change: in the hands of value creation opportunities for the company. In conjunction with our new shareholders, Elliot and investment management.
First, welcome, Stephen Bogg.
A. K. Say.
Mark and Yeti, and Paul Tograves to our board.
Speaker Change: Each brings significant professional and industry experience and will add fresh perspectives as we continue to execute our strategy.
Speaker Change: Identify the best avenues for further growth and value creation.
Speaker Change: I would also like to sincerely thank the four members of our board who are not seeking reelection.
Bob Bertilini, Debbie Cochiever, George Massaro, and Richard Waldman.
Speaker Change: I appreciate that you are a key strategic counsel that each of you have provided to the company and to me over the many years that you have served on our board, which have contributed to our enduring industry leadership and we wish each of you the very best.
Speaker Change: In addition, the Strategic Planning and Capital Allocation Committee of our Board will undertake a comprehensive strategic review of our business to evaluate initiatives to unlock additional value.
Speaker Change: We're going back on the outcome of the boys review once complete.
Speaker Change: I look forward to working with each of our new and continuing board members and the Elliott team as we focus on maximizing long-term value for our investors.
Clients and M40s. I firmly believe the company shares
Speaker Change: are significantly undervalued, particularly after the FDA's announcement last month. So implementing additional value creation initiative is both of them.
Terry and Timely.
Speaker Change: I'd like to thank our employees for their exceptional work and commitment and our clients and
Flavia Pease: Marketing and Support. Now, Flavia will provide additional details on our full financial performance
Thank you Jim, and good morning.
Flavia Pease: Before I begin, may I remind you that I'll be speaking primarily to non-GAAP results, which
Flavia Pease: Cost-related primarily to restructuring actions, gains or losses from certain venture capital and other strategic investments and certain other items.
Flavia Pease: Many of my comments will also refer to organic revenue growth, which exclude the impact of acquisitions, and foreign currency translation.
Flavia Pease: We're pleased that our first quarter revenue and known gap earnings for share exceeded our prior outlook
Flavia Pease: This outcome was primarily driven by better than expected DSA results, and to a lesser extent a lower tax rate.
Thanks for watching!
Flavia Pease: These results also reflect the actions we have taken to protect the operating margin.
Flavia Pease: For the past two years, we have been in the aggressive actions through our restructuring program to reduce our cost structure by over 5% in the line our infrastructure.
Flavia Pease: with the first man, which contributed to the first quarter operating margin improvement and earnings growth, even with the modest revenue decline.
Flavia Pease: We remain on track to deliver annualized cost savings of over 175 million dollars in 2025. And
and $25 million in 2026.
David Windley, Ann Hynes,
Flavia Pease: continuing to deploy capital in a discipline and shareholder's focus manner, as announced last quarter.
Flavia Pease: We're leveraging our solid annual free-class flow transformation and completed the repurchase of $350 million in shares during the first quarter of 2025.
Flavia Pease: for modeling purposes, including the stock repurchases to date, we will have slightly below 50 million average diluted shares outstanding for the full year.
Flavia Pease: Just over two quarters, since the $1 billion stock repurchase program was authorized, we have repurchased nearly half of this amount.
Speaker Change: As Jim referenced, we currently believe the company is significantly under value and will closely review opportunities for value creation, including additional stock repurchases.
Speaker Change: We also experienced a significant increase in quarterly cash flow, with $112.4 million generated in this quarter compared to $50.7 million last year.
Speaker Change: The improvement was primarily driven by lower performance space cashfulness payments for 2024, which are the first quarter and by lower capital expenditures.
Speaker Change: was $69.3 million, or approximately 6% of revenue in the first quarter, compared to $79.1 million last year, reflecting the ongoing moderation of occupacity investment.
in the current domain environment.
Speaker Change: For the year, we expect that free cash flow will be $350 to $390 million, and cat-packs will be approximately $230 million, consistent with our prior outlook.
Speaker Change: As Jim mentioned, we have modestly raised our revenue and non-GAAP earnings for share guidance.
We now expect a full year reported revenue.
Speaker Change: will decline 3.5 to 5.5 percent, and organic revenue will decline 2.5 to 4.5 percent.
Speaker Change: Effects rates have been volatile since the election. And as a result, we now expect foreign exchange which will represent an amount of $1 per cent headwind to 2025 revenue based on recent bank forecasts.
Speaker Change: which is favorable to our prior outlook of a 1 to 1.5% headwind.
Speaker Change: Non-depth earnings per share are expected to be in a range of $9.30 to $9.80.
Speaker Change: Our updated segment revenue outlook for 2020-25 can be found on slide 36.
Speaker Change: We're raising our DSA outlook to reflect a solid first quarter performance, including improved bookings which give us greater confidence in the near term.
Speaker Change: We're also covering our IMS outlook, reflecting headwinds related to our creative business, and potentially on our academic and government updates later in the year. Our matching and factoring outlook is unchanged on an organic basis.
Speaker Change: We expect a consolidated operating margin would decline 20 to 50 basis points in 2025 or largely consistent with our high outlook of modestly lower.
I will now provide details on the non-operating items.
dedicated to our first quarter performance versus the prior year.
Speaker Change: Unallocated corporate costs totaled $52.4 million in the first quarter, all 5.3% of revenue compared to 6.2% of revenue last year.
Speaker Change: The decrease was primarily due to the benefits of cost-giving actions.
Speaker Change: For the full year, we expect unallocated corporate costs will be in a range of 5 to 5.5% of total revenue.
The Nondead Tax Race
Speaker Change: quarter, was 22.7 percent, represent the decrease of 60 basis points year over year.
Speaker Change: The first quarter tax rate was slightly favorable to our prior outlook.
Speaker Change: to primarily to the timing of the enactment of certain people in the taxes.
as well as the high R&D tax credits. [inaudible]
Speaker Change: For the full year, we continue to express our non-tapped actions.
Speaker Change: will be in the range of 22.5 to 23.5% consistent with our prior outlook.
Speaker Change: I'd like to briefly address the recent headlines around tariffs. Based on the current universal tariffs in place as of May 7th, we expect a limited direct impact on an annual basis.
Speaker Change: and other study-related items, and we plan to offset most of these estimated tariffs by passing along the higher costs.
This has been factored in our current guidance.
Speaker Change: For the full year, we expect total net interest expense will be at the end of our prior outlook of 112 to $117 million.
Speaker Change: At the end of the first quarter, we had outstanding $2.5 billion with a progress of 60% at a fixed interest rate.
Speaker Change: A summary of our 2025 financial guidance can be found on slide 40.
Speaker Change: Looking ahead to the second quarter, we expect reported and organic revenue will decline.
Speaker Change: So mid single digit rate year over a year.
Speaker Change: Earnings per share I expect it to improve nicely from that.
Speaker Change: Level with EMEA.
Speaker Change: High single digit sequential increase over the $2 and 34.
Speaker Change: In summary, we were pleased that our financial performance in the first quarter benefited from the disciplined implementation.
Speaker Change: The cost saving initiatives that we undertook.
Speaker Change: And we will remain focused on continuing to evaluate additional opportunities to drive future savings and operating efficiencies.
These actions are important not only to align our operations with the current demand and to protect the operating margin.
Speaker Change: Also as a means to allow us to continue.
Speaker Change: And our businesses.
Speaker Change: We are committed to being at the forefront of scientific innovation, particularly as the industry continues to evolve.
Speaker Change: Our strategic investments and scientific expertise will position us to actively shape, the changing regulatory landscape, while maintaining the highest standards of safety and efficacy.
Speaker Change: We will also evaluate all opportunities to unlock value with the support of our new and continuing board members and Elliott investment management.
Speaker Change: We're proud of the foundation, we've built and we are energized.
Speaker Change: Please go ahead. Thank you.
Speaker Change: That concludes our comments, we will now take your questions.
Speaker Change: Thank you at this time, if you would like to ask a question. Please press star one on your telephone keypad.
Speaker Change: You may remove yourself from the queue at any time by pressing star Q and the interest of time.
Speaker Change: Mr. Zhu please limit yourself to one question and one follow up.
Speaker Change: Once again that is star one to ask a question.
Speaker Change: We will pause for just a moment to allow questions to queue.
Speaker Change: Thank you our first question will come from Max Smock with William Blair. Your line is open.
Max Smock: Hey, good morning, Thanks for taking the question.
Speaker Change: Maybe just starting off with the FDA guidance.
Speaker Change: Really on the news yesterday I'm wondering if you have any thoughts.
Speaker Change: Whether some of the mixed messaging from the FCA will develop.
Speaker Change: Developers from really leaning into the guidance about reduce it.
Speaker Change: Okay.
Speaker Change: On one hand, there has been a lot of talk about improving the drug development process.
Speaker Change: Maybe to bring drugs to market.
Speaker Change: Yesterday, we.
Speaker Change: Dr Prasad is head of seeber.
Speaker Change: Thank you.
Speaker Change: Basically that that person's a conflicting message based on <unk>.
Speaker Change: Comment so based on your conversations with pharma in particular could this be more like what we saw with the FDA.
Foundation to point O ask Cory didn't really lead to any real changes or is this more.
Speaker Change: Thank you.
Craig: Really interesting where you Craig.
Craig: And there's lots of changes at the FDA.
Craig: Everybody has different opinions on the impact.
Craig: There are less people.
Craig: This new leadership.
Craig: It's difficult to judge where that is ongoing.
Craig: I guess, we would just say that.
Tony: This is Tony.
Craig: So this initiative.
Speaker Change: Significant amount of time, we and others have been participating in the development of Nims.
Our focus on monoclonal antibodies. This is probably an intelligent place too.
Speaker Change: And do a pilot.
Speaker Change: Right.
Speaker Change: We're excited about the opportunity however, this development.
Speaker Change: To be to lead to lead the charge in sort of clients in sync with the regulatory agencies both of them.
Speaker Change: This country.
Speaker Change: And in other places so.
Speaker Change: Fact that.
Speaker Change: We all would like to see.
Speaker Change: <unk> continued to refine that.
Speaker Change: Utilization.
Speaker Change: Hi.
Speaker Change: This has been going on for a significant amount of time.
Speaker Change: That will continue.
Speaker Change: Next will be the principal driver of all of this.
Speaker Change: A lot of validation will be required.
Speaker Change: Play a key role.
Speaker Change: So.
Speaker Change: I think your question is really around the pace and the cadence of that.
Speaker Change: It's really difficult to say I think if there were no changes in the FDA in terms of staffing our leadership.
Speaker Change: The validation methodology.
Speaker Change: We will take a meaningful amount of time probably.
Speaker Change: Probably a little bit less with monoclonal antibodies longer term NXP monoclonal antibody studies, which is where they started.
Speaker Change: That's going to be sort of a proof of principle.
Speaker Change: There'll be some development there.
Speaker Change: <unk>.
Speaker Change: Regardless of what's going on with the FDA.
Speaker Change: Got it Super helpful commentary.
Speaker Change: Following up and I appreciate the detail you shared during the call around how alternative approaches are being used today a lot of inbounds, we've got have been around.
Speaker Change: Stimulation in particular, <unk> and <unk> just.
Speaker Change: Just wondering if you can provide some more detail.
Speaker Change: Each of those offerings.
Speaker Change: Currently and why they are being used more frequently already in preclinical and then what you view as kind of the biggest hurdle for adoption of those biosimilar approaches moving forward. Thank you.
Speaker Change: I mean, a lot of those technologies are used successfully early on Android.
Speaker Change: More than safety, because you're looking for.
Speaker Change: A single answer.
Speaker Change: With something that you're questioning are prosecuted or developing.
Speaker Change: By the way I would say that most of the drug companies certainly the large ones have their own proprietary technologies and using those.
Speaker Change: Okay.
Speaker Change: Kevin.
Speaker Change: Certainly not sharing them.
Speaker Change: With others.
Speaker Change: To move this.
Speaker Change: Regulated tox.
Speaker Change: Looking at the systemic reaction of a dragon multi.
Speaker Change: Okay.
Speaker Change: <unk> is really complicated science.
Speaker Change: Trying to simulate things that happen inside of a human body as opposed to actually using a whole animal system to actually see how it works inside of them.
Speaker Change: The Malian system is quite different.
Speaker Change: Okay.
Speaker Change: Huge leap of faith.
Speaker Change: So I.
Speaker Change: I think it's going to be a slow build.
Speaker Change: Okay.
Speaker Change: These are going to be beneficial.
Speaker Change: Some of them will be beneficial to discovery and maybe not.
Speaker Change: Yeah.
Speaker Change: And I think that continued investment.
Speaker Change: Oscar and others.
Speaker Change: And as I said in a proprietary nature of our client is necessary and important.
Speaker Change: In the final analysis, the FDA and all the other regulatory agencies.
Speaker Change: Principally.
Speaker Change: Thanks.
Speaker Change: Ensuring the safety.
Speaker Change: Patients with this drug.
Speaker Change: Cut any corners to do that.
Speaker Change: Even with what looks like exciting technology. So it is going to be a slow.
Speaker Change: Continue to build.
Speaker Change: Thanks again for taking the questions.
Speaker Change: Thank you.
Speaker Change: Question will come from Eric Coldwell with Baird. Your line is open.
Speaker Change: Yeah.
Speaker Change: I guess I'll stick with the same general line of questions.
Speaker Change: Max.
Speaker Change: I'm curious on <unk> list.
Speaker Change: Upwards of a dozen areas.
Speaker Change: Things that you've been doing $200 million of annualized revenue broadly defined.
Speaker Change: Where does Charles River, where do you feel you stand out the most where you're truly an industry thought leader.
Speaker Change: You don't have maybe higher share versus competitors.
Speaker Change: And then what areas do you feel you're underrepresented in today, but might step up investment.
Speaker Change: And I guess part part C of that is our unit.
Speaker Change: Or willing to interested in.
Speaker Change: Doing additional.
Speaker Change: Okay.
Speaker Change: Further supplement or complement what you're doing in the Nims category. Thank you very much.
Eric: The last piece Eric.
Speaker Change: Because it's.
Speaker Change: Interesting.
Speaker Change: So we bought on microbial business.
Speaker Change: Yes.
Speaker Change: As the only FDA approved alternative to using research models.
Speaker Change: That's been a very successful business for us as you know and we assumed and presume.
Speaker Change: Now 30 years later, we would have made I don't know dozens of acquisitions in this space.
Speaker Change: Just because the trajectory of new science, and the necessity to be more sophisticated and half.
Speaker Change: Additional refinements.
Speaker Change: And we see I don't know a dozen or so companies.
Speaker Change: Companies annually.
Speaker Change: Yes.
Speaker Change: Let me say it before.
Speaker Change: Yes.
Speaker Change: Apologies if it comes at a somewhat academic.
Speaker Change: Academic institution of the government and you better bias, because we're going to take.
Speaker Change: I'll just put you out of business.
Scott: Conversation Scott.
Speaker Change: Okay.
Speaker Change: Thanks look interesting, but not practical and then not consistent and they're not valid validate a bow and then certainly not replacement for whole animal systems or even.
Speaker Change: Anything that can be augmented it so there are a few things.
Speaker Change: We look at it.
Speaker Change: Periodically.
Speaker Change: Okay.
Speaker Change: Ah recently.
Speaker Change: As of this FDA.
Speaker Change: I would say as a general proposition with quite interest.
Speaker Change: In licensing or acquiring technologies that really work really helped.
Speaker Change: Product development.
Speaker Change: Cut any corners in risk patient safety so.
Speaker Change: Yeah pretty much very much committed to that.
Speaker Change: And yes, we've done we've done a whole host of things.
Speaker Change: We have bought some companies we are a company called retro Janice.
Speaker Change: So microwave technology, you're looking for.
Speaker Change: Off target effects.
Speaker Change: And off target effects.
Speaker Change: That's really really important defined.
Speaker Change: We launched.
Speaker Change: The program to use virtual control.
Speaker Change: Set of whole animals.
Speaker Change: Because these studies we have a.
Speaker Change: Collaborative deal going which peers.
Speaker Change: Our company's AI technology with.
Speaker Change: Traditional methods to see whether we can accelerate.
Speaker Change: Helping our clients.
Speaker Change: Uh huh.
Speaker Change: Yeah.
Speaker Change: And we've had a couple of days it was previously.
Speaker Change: Previously.
Speaker Change: Okay, Alright, well certainly continue to look.
Speaker Change: We also have.
Speaker Change: And we started this probably 15 years ago.
Speaker Change: Our clients were not really.
Speaker Change: Our clients have some problems.
Okay.
Speaker Change: Yes, we have years and years.
Speaker Change: Toxicology.
Speaker Change: Some clients.
Speaker Change: I would like to use.
Speaker Change: <unk> basis.
Speaker Change: <unk> indicated what the client is so what's the driver.
Speaker Change: Helping to design more predictive preclinical trials.
Speaker Change: Something that we will Lea County that will lead I think we have the best technology doing that I think thats under represented under represented to go back to you.
Speaker Change: Okay. Good question so.
Speaker Change: We have stated commitment we have an alternative methods advanced with project.
Speaker Change: Okay.
Speaker Change: Focus on that.
Speaker Change: We bring in.
Speaker Change: Okay.
Speaker Change: What's the nature of the science.
Speaker Change: What's practical what's.
Speaker Change: What's beneficial what should we have.
Speaker Change: Okay.
Speaker Change: Portfolio.
Speaker Change: We will we will continue to do that.
Speaker Change: Thoughtfully.
Speaker Change: We continue to spend money doing that without being wasteful.
Speaker Change: And again first and foremost we will continue to be all about the science.
Speaker Change: And in any way.
Speaker Change: Cause our clients to be risking patient safety.
Speaker Change: Thank you our next question.
Speaker Change: Comes from Elizabeth Anderson with Evercore ISI.
Speaker Change: Your line is open.
Speaker Change: Hey, guys. Thanks.
Speaker Change: Thanks, So much for the question I have two questions. My first question maybe.
Speaker Change: <unk> is just in the short term as you talk to customers since this FDA announcements.
Speaker Change: Any action.
Speaker Change: Particularly now that they're starting to get more change there.
Speaker Change: <unk> procedures.
Speaker Change: Can you still sort of in digestion mode on that.
Mike: And then Mike.
Mike: Question, just if we look at the strength in the bookings in the first quarter that was nice to see were there any timing items. Just in terms of are you still seeing sort of.
Mike: Would you characterize that you are still seeing sort of a continued environment into the second quarter. Thank you.
Mike: So I think.
Mike: Customers.
Mike: Okay.
Mike: We're pleased with the job.
Mike: Tone.
Mike: The FDA has pronounced albeit pretty dramatic.
Mike: My point of view.
Mike: That they wanted to participate in additional technologies and methodologies to accelerate getting the drugs to market.
Mike: Maybe reduce the cost.
Mike: Maybe have more sophisticated.
Mike: Right.
I said a lot of.
Mike: <unk> technologies.
Mike: I don't think we'll see.
Mike: Any sort of dramatic change in methodology for doing safety.
Mike: Safety studies.
As you.
Mike: Yeah.
Mike: I have read.
Mike: The Fda's focus.
Mike: Longer time term HP studies.
Mike: This is something that they have been waiving the necessity to do those lines in terms of.
Mike: Some period of time, so the drug companies are already participating in that.
Mike: Yes.
Mike: Much less toxicity signals with monoclonal antibodies and they tend to lend themselves to this sort of initiative so that will save.
Mike: The companys time and money.
Mike: And we're certainly happy.
Mike: Okay.
Mike: So.
Mike: Okay.
Mike: Hi, Jeff.
Mike: Yes.
Fundamentally change anything that you're doing.
Mike: Got it.
Mike: Had a couple of times with previous questions.
Mike: Their job is to.
Mike: Develop drugs.
Sure diseases, but sure patient safety, so they'll do everything they can do that.
Mike: I can do that partially with new technologies that's great.
Mike: We think that.
Mike: Longer term there will be a hybrid approach where.
Mike: Clients.
Mike: Animal data.
Mike: The IMS data.
Mike: Time and the combination.
Mike: So to answer my questions.
Mike: Yeah.
Mike: Yes.
Mike: The regulatory agencies.
Mike: Yes.
Mike: Okay.
Mike: This will be a journey.
Mike: These new technologies will be beneficial for sure.
Mike: Drugs, particularly at the moment monoclonal antibody is going to be a lot harder.
Mike: Hey go after small molecules or large molecules like cell and gene therapy, that's just much less.
Mike: Around them and the toxicity issues.
Mike: Implex.
Mike: And you really want to use the whole animal assistance to see what the multiple of Oregon.
Mike: <unk>.
Mike: To the drug.
Mike: So whether it's.
Mike: Alright injected second.
Mike: Second question was about bookings.
Mike: He is going to answer that.
Mike: The strength of bookings in the first quarter was indeed, indeed encouraging is the first time.
Mike: Okay.
Mike: I went to about one.
Mike: For two years and.
Mike: There was really no one timer impacting dot I was broadly.
Mike: Okay.
Mike: Okay.
Mike: And my follow a strong but cancellations were down across.
Mike: Segment so.
Mike: It's just.
Mike: Operationally strong, although still only one quarter.
Mike: Thank you.
Speaker Change: Thank you. Our next question will come from Ann Hynes with Mizuho Securities. Your line is open.
Ann Hynes: Great. Thanks, Thanks for all the detail very helpful.
Ann Hynes: I guess like when I listen to your presentation.
Ann Hynes: I feel like you don't think that this FCA issue.
Ann Hynes: Take negative impacting growth. So if I look at your long term CAGR that you gave a pre this market downturn with 6% to 8%.
Ann Hynes: And DSA.
Ann Hynes: Assuming things like now this market downturn has happened what do you think over time this FDA changed but how would that impact that kind of long term growth algorithm for your company.
Ann Hynes: My first question and then my second question can you just comment on pricing I know pricing has been a pressure, but it's definitely better than maybe what happened during the great recession. So can you tell us what happened.
Speaker Change: That periodic burst is what pricing is doing now that'd be great. Thank you.
Ann Hynes: Thank you.
Speaker Change: Long term growth.
Speaker Change: Trajectory.
Speaker Change: FDA initiative.
Speaker Change: We have extensive time refreshing our long term growth rate.
Speaker Change: For a while.
Speaker Change: Yes.
Speaker Change: This new information into consideration with our own assessment and feedback from our clients and experts.
Speaker Change: Shield will.
Speaker Change: Have a refreshment of our long term.
Speaker Change: Okay.
Speaker Change: Probably when we have our investor day.
Speaker Change: And have a comprehensive.
Speaker Change: Review and assessment of that so I would stop short of throwing out numbers.
Speaker Change: It's early days.
Speaker Change: You want to take the pricing question sure.
Speaker Change: So yes pricing environment.
Speaker Change: Improved slightly in the first quarter.
Speaker Change: Driven primarily by mix.
Speaker Change: Especially longer duration specialty studies, where we tend to have a look.
Speaker Change: A bit more.
Okay.
Speaker Change: Power.
Speaker Change: <unk> not have to discount as much.
Speaker Change: So that was encouraging.
Speaker Change: And when you talk about comparing the price the current price environment you.
Speaker Change: The great financial crisis, indeed, very very different.
Joanne: Thanks Joanne.
Joanne: Capacity has been better managed.
Joanne: There is.
Joanne: Outsourcing is more prevalent now so we're definitely not seeing the severity I would say of price pressure or price decline compared to.
Joanne: Great financial crisis, although as we said last year.
Joanne: We and others in the industry.
Joanne: As the demand contracted a bit.
Joanne: To selectively adjust for I think so it's obviously not.
Joanne: I've been doing sort of COVID-19.
Joanne: Okay.
Joanne: You said in the first quarter things were stable from a spot perspective.
Joanne: Helped with our price mix.
Joanne: Our results.
Joanne: Great. Thank you.
Speaker Change: Thank you. Our next question will come from Dave Windley with Jefferies. Your line is open.
Dave Windley: Hi, Thanks for taking my questions.
Speaker Change: And just asked so I'm going to try to ask in a slightly different way.
Speaker Change: Flavio just can you just walk through some of the history on pricing.
Speaker Change: I think if I remember.
Speaker Change: Comments from last year correctly that some time in the earlier part of the year was win.
Speaker Change: Pricing demand and volume demand tended to drop our did drop in.
Speaker Change: Price levels kind of dropped in the spot market.
Speaker Change: And you described that as kind of stepping down once and then continuing now to plateau.
Speaker Change: And then that goes.
Speaker Change: Backlog and then that backlog beginning.
Speaker Change: <unk> revenue that lap that lower.
Speaker Change: Lap the higher pricing and you started.
Speaker Change: Pricing in the fourth quarter, So I guess, what I'm trying to understand because you had described that as a plateau.
Speaker Change: Lower plateau that.
Speaker Change: We would see fairly consistently.
Speaker Change: Pressured pricing <unk> and forward so I wanted to understand.
Speaker Change: Why is that cadence is fluctuating number one and then number two.
Speaker Change: S O T E.
Speaker Change: The discussion there really was about another step down in price pressure by all players in the market and so I just want to make sure I am I.
Speaker Change: Im understanding or maybe I'm misunderstanding, new launch or something like that.
Speaker Change: But we really did hear from a number of players that the price environment.
Speaker Change: Started 2025.
Speaker Change: More pressured and how it exited 2000 okay.
Speaker Change: I appreciate your comments on that.
Speaker Change: Sure.
Speaker Change: Good morning, let me take the second part of your question. So I can't call I cannot comment on others, but from our pricing perspective.
Speaker Change: I would say is as we indicated in our prepared remarks that the slot prices stable.
Speaker Change: In the first quarter sort of compared to how we work.
Speaker Change: Josh.
Speaker Change: And then.
Speaker Change: Just walk around.
Speaker Change: All right.
Speaker Change: Youre correct in how you were.
Speaker Change: Okay.
Speaker Change: This allowance.
Speaker Change: We started doing last year, and how that would matriculate through the backlog and eventually revenue I think was positive favorable which maybe a little bit of a surprise is the impact.
Speaker Change: As I said before so the.
Speaker Change: The first quarter.
Speaker Change: Hi, Sachin.
Speaker Change: Improved primarily driven by that makes sense.
Speaker Change: Got it and then if I could ask a separate topic.
Speaker Change: Does how the.
Speaker Change: Each funding and.
Speaker Change: Mike.
Speaker Change: Business.
Speaker Change: That funding flows I think you're maybe you are doing.
Speaker Change: Exposure is very very low so maybe the direct risk.
Speaker Change: Is is not really significant at all I Wonder if you if you have.
Speaker Change: A clear assessment of how many.
Customers say away from NIH are dependent on NIH funding.
Speaker Change: I think you've said in the past that that funding tends to get.
Let out on kind of a three year rolling bases and I'm wondering if that provides some protection as it relates to the current NIH proposed cuts.
Speaker Change: We have a couple of them.
Speaker Change: Percentage points of our revenue directly related to NIH.
Speaker Change: Their client base.
Speaker Change: Research model business.
Speaker Change: We have a lot of long term contracts.
Speaker Change: I gotcha.
Speaker Change: With the government.
Speaker Change: Okay.
Speaker Change: Yes.
Speaker Change: Interrupting those contracts.
Speaker Change: Sure.
Speaker Change: Yes.
Speaker Change: Okay.
Speaker Change: Really specialized animal models with different agencies.
Speaker Change: Thanks, Chris.
Chris: You said, there's a lot of dialogue reductions with Eni.
Speaker Change: Speculating, we haven't heard anything.
Speaker Change: We don't have any adverse impacts from the government.
Speaker Change: Okay.
Speaker Change: If you look at academic and government U S.
Speaker Change: It's probably 20% of the RMS.
Speaker Change: Revenue.
Speaker Change: Thank you.
Speaker Change: Indirect money from the government.
Speaker Change: In other places.
Speaker Change: Again, we have no indications yet.
Speaker Change: What the impact might be as we said we were being very cautious in terms of our long term.
Speaker Change: Got it. So this year just assuming that we will have some adverse attached to that we also said that since.
Speaker Change: It's already in May.
Speaker Change: Nothing has happened yet.
Speaker Change: Whatever path, we have we'll probably be in the back half of this year, perhaps next year.
Speaker Change: So we'll let you all know.
Speaker Change: What actually transpired.
Speaker Change: So predicting.
Speaker Change: Yes.
Speaker Change: Well, we're obviously.
Speaker Change: Take that the contracts we have.
Speaker Change: Yeah.
Speaker Change: From a basic research a whole bunch of different agencies.
Speaker Change: Pretty short sighted for the government.
Speaker Change: To do anything with those.
Speaker Change: And just to.
Speaker Change: Thank you Jim coded correctly NIH.
Speaker Change: 2% of total company and then I think you talked about.
Speaker Change: Plus academia being about 20% North America, 20% of RMS.
Speaker Change: About 6% of total revenue.
Speaker Change: Total company.
Speaker Change: Alright.
Speaker Change: Great. Thank you. Thanks.
Speaker Change: Thank you our next question will come from.
Speaker Change: <unk> with Bank of America. Your line is open.
Speaker Change: Great.
Speaker Change: Two questions I have two hopefully quick ones one on the going back to the GSA strengthen the bookings activity in the quarter.
Speaker Change: Just wanted to dive in order to deeper into the improvement you saw on Q, you specifically called out.
Speaker Change: <unk> was a quicker start dates reflective of their short term booking behavior.
Speaker Change: I mean could you expand on that what do you think exactly drove that and then just a question on <unk>.
Speaker Change: Could that be sustainable for the rest of the year could that be a little bit of a pull forward versus <unk>.
Speaker Change: Okay.
Speaker Change: What are the dynamics, there with pharma and biotech.
Speaker Change: Bookings.
Speaker Change: You've got clients.
Speaker Change: Thanks for your.
Speaker Change: At this time.
Speaker Change: We had available capacity, so that worked really well.
Speaker Change: So quick Scott.
Speaker Change: Obviously extremely.
Speaker Change: So to the first quarter TSA.
Speaker Change: <unk>.
Speaker Change: Got it.
Speaker Change: What we've said is we can't anticipate that that will continue.
Speaker Change: It would be nice.
Speaker Change: We don't have any indications that that will continue so I would say anything is possible.
Speaker Change: Definitely not a guidance.
Speaker Change: Yes.
Speaker Change: Good morning.
Speaker Change: Okay.
Speaker Change: If that continues we'll obviously.
Speaker Change: Let you folks know.
Speaker Change: We anticipate a little bit unusual.
Speaker Change: Again, it's tied to having the capacity so.
Hi, Dave.
Speaker Change: We may have used up the people that.
Speaker Change: Okay.
Speaker Change: Thanks, Robert quickly that Hasnt been the case the last few years, it's a little bit unusual. This is sort of back up work that people wanted to get that done.
Speaker Change: Quickly.
Speaker Change: Yes.
Speaker Change: Not guiding to the continuation of I guess, yes.
Speaker Change: Okay.
Speaker Change: Okay, and then for my follow up.
Speaker Change: In terms of the changes to the board.
Speaker Change: The agreement with Elliott realize Youre, just beginning the strategic review, but could you lay out.
Yeah.
Speaker Change: Questions you will be looking at whether what are you considering is it.
Speaker Change: Okay.
Speaker Change: Divestment.
Speaker Change: Any type of reward.
Speaker Change: Sure.
Speaker Change: A whole company transaction, just what are the different avenues you're exploring.
Speaker Change: Thanks.
Speaker Change: So as you said, we haven't committee of the board.
Speaker Change: Okay.
Speaker Change: Capital allocation Committee.
Speaker Change: We do.
Speaker Change: Thank you.
Speaker Change: Some of the parts analysis looks at it hopefully.
Speaker Change: Okay.
Speaker Change: And our M&A and see whether we're happy with that and we talk strategically about things that we should add to the portfolio.
Speaker Change: Okay.
Speaker Change: We have three new members.
Okay.
Speaker Change: And those are three of the four.
Speaker Change: New directors that we have one of whom is actually.
Speaker Change: Senior employee.
Speaker Change: So.
Hi.
Speaker Change: And I have on that.
Speaker Change: Former directors, but it's an opportunity to take a fresh look at the whole portfolio.
Speaker Change: Competitive dynamics of every business that we're in where we think they are going what the chart.
Speaker Change: Sure.
Speaker Change: What if anything is missing in the portfolio and what if anything can be.
Speaker Change: Thank you Scott contributing the way we would like so.
Speaker Change: It would be premature.
Speaker Change: Yes, what the outcome would be I think we are going to be.
Speaker Change: <unk>.
Speaker Change: Open minded.
Speaker Change: Well.
Speaker Change: Very objective.
Speaker Change: Decision.
Speaker Change: This committee is going to be hard at work.
Speaker Change: Thank you.
Speaker Change: Tire company.
Speaker Change: Okay.
Speaker Change: We would be.
Speaker Change: Businesses are going.
Speaker Change: We'll see what.
Speaker Change: But that process with you.
Speaker Change: Relatively quickly without rushing.
Speaker Change: Thanks, Steve.
Speaker Change: Mrs.
Speaker Change: Thanks, so much.
Speaker Change: Okay.
Speaker Change: Thank you. Our next question comes from Justin Bowers with Deutsche Bank Your line.
Speaker Change: Line is open.
Justin Bowers: Hi, good morning, everyone.
Speaker Change: I wanted to go back to.
Speaker Change: Mike's first question.
Speaker Change: Faster.
Speaker Change: Thanks, Tom.
Speaker Change: Okay.
Speaker Change: You've seen continue.
Speaker Change: <unk>.
Speaker Change: Through May number one number two.
Speaker Change: I wasn't sure. If you said that that was isolated to large pharma or is that something that you saw more broadly.
Speaker Change: Our treated that.
Speaker Change: Tien tsin.
Speaker Change: Yes.
Speaker Change: Hi.
Speaker Change: Booking patterns or Austin.
Speaker Change: What programs or <unk>.
Speaker Change: Large pharma customers.
Speaker Change: Yes.
Speaker Change: For the year.
Speaker Change: Yes.
Speaker Change: Sure.
Speaker Change: I have been doing it fast.
Speaker Change: Across the across the board so clients that had teed up.
Speaker Change: We're excited to get going.
Speaker Change: Boeing.
Speaker Change: Revenue.
Speaker Change: This quarter was stronger.
Speaker Change: That's followed by clients.
Speaker Change: Okay.
Speaker Change: Bookings were stronger.
Speaker Change: With with pharma.
Speaker Change: Some of the pharma companies have work.
Speaker Change: The reduction in their infrastructure portfolios.
Speaker Change: That takes a lot of the biotech companies themselves.
Speaker Change: With axis capital.
Speaker Change: I presume that the capital markets will be open this year.
Speaker Change: Okay.
Speaker Change: Clearly.
Speaker Change: So.
Speaker Change: The SaaS.
Speaker Change: This is probably a one quarter phenomenon, but we will see how that.
Speaker Change: As I said earlier.
Speaker Change: Usual.
Speaker Change: Okay.
Speaker Change: Okay.
Okay.
Speaker Change: Excess capacity at the time with these guys.
Speaker Change: Typically not something we see that we can predict.
Speaker Change: And I think just.
Speaker Change: Okay.
Speaker Change: We think these let's say foster stereotypes, even though again, we don't provide a lot of intra quarter. So.
Speaker Change: Okay.
Speaker Change: What we've seen in Q1 also does give us visibility to the second quarter. So I'd say the Quaker starts are going to be affecting both Q1 and Q2. So the first half of the year I think what Jim correctly.
Speaker Change: We're not necessarily counting or assuming that that's going to continue given that current visibility is somewhat shorter.
Speaker Change: Certainly.
Speaker Change: That's a positive the first half.
Speaker Change: Okay.
Speaker Change: And then just pivot.
Speaker Change: Pivoting a bit.
Speaker Change: Ben.
Speaker Change: A decent uptick.
Speaker Change: Licensing deal.
Speaker Change: Auto China over the last few quarters.
Speaker Change: And was just hoping you could help us think through sort of the pushes and pulls on the business. Both here in the U S and then locally in China.
Speaker Change: Some of the opportunities that may be congrats there.
Speaker Change: Dynamic.
Speaker Change: Okay. This is the continuing saga by the big drug companies right.
Speaker Change: Smaller biotech companies quite innovative.
Speaker Change: On the discovery engines for Big pharma.
Speaker Change: Licensing.
Speaker Change: Right.
Speaker Change: In the U S and.
Speaker Change: And we are certainly beginning to see.
Speaker Change: Okay.
Speaker Change: Yes.
Speaker Change: In biotech companies in China as well.
Speaker Change: I think that will continue.
Speaker Change: I think that's the smart thing for them to do.
Speaker Change: Neither of those has a particularly.
Speaker Change: Significant impact on us one way or another.
Speaker Change: Okay.
Speaker Change: Our business in China.
Speaker Change: Well supporting the investment.
Speaker Change: Aerotech and big pharma in China.
Speaker Change: We'll continue.
Speaker Change: And we hope to continue to do work.
Speaker Change: The preclinical study.
Speaker Change: But the larger companies when they do.
Speaker Change: Thank you.
Speaker Change: Alright Thats helpful.
Speaker Change: Yes.
Speaker Change: Thanks, Patrick.
Speaker Change: Patrick.
Speaker Change: Good morning.
Speaker Change: For right now.
Speaker Change: Okay.
Speaker Change: Biotech so.
Speaker Change: Did that sort of cadence is definitely going to continue.
Speaker Change: But the big drug companies, particularly as they face.
Speaker Change: Patent cliff.
Speaker Change: It's better for them.
Speaker Change: Okay.
Speaker Change: Yes.
Speaker Change: Congrats on logo.
Speaker Change: Well.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Thank you. Our next question will come from Karl crews with UBS. Your line is open.
Karl crews: Hi, Thank you for taking the questions Hi briefly going through the manufacturing segment could you discuss what youre seeing within the.
Speaker Change: The CD Moe.
Speaker Change: The end market demand within that business and how you view Charles River as current competitive positioning there and what happens.
Speaker Change: In Q1.
Speaker Change: Yes so.
Speaker Change: Biologics testing Austin.
Speaker Change: Is it seasonal.
Speaker Change: Impact.
Speaker Change: First quarter impact.
Speaker Change: Got to predict and those that work comes in.
Speaker Change: Yeah.
Speaker Change: Almost without warning.
Speaker Change: Quickly and as we said we would play.
Speaker Change: And positive about the cadence of the biologics.
Speaker Change: For the balance of the year.
Speaker Change: I think that this will be high.
Speaker Change: On the CDM ourselves.
Speaker Change: Manufacturing business, we have.
Speaker Change: We have a reduction in revenue from a couple of big commercial clients that we've talked about significantly previously.
Speaker Change: I would say that if you put those aside the underlying demand is pretty good right now.
Speaker Change: Besides the gene therapy side as well.
Speaker Change: We have several clients that are in late stage clinical.
Speaker Change: Couple of instead of talking to us.
Speaker Change: The commercialization.
Speaker Change: Okay.
Speaker Change: We have.
Speaker Change: Really strong SaaS, they're in a facility that's in great shape.
Speaker Change: Hello.
Speaker Change: My question relates.
Speaker Change: To support the commercial clients, even though our revenue with them is declining and so yeah, we feel.
Speaker Change: We've said that the over arching dimmed.
Speaker Change: First LNG.
Speaker Change: We thought it would be when we first acquired this company.
Speaker Change: Yes.
Speaker Change: Over arching reality that there is a lot of concern about the safety profile of these drugs and that there'll be slow to uptake slowly get into market.
Speaker Change: There's still a lot of them in the pre clinical arena.
Speaker Change: Right.
Speaker Change: We're working hard on that business.
Speaker Change: We're committed to growing it.
Speaker Change: So the client basis reasonably strong right now.
Speaker Change: Great. Thank you.
Speaker Change: Thank you. Our next question comes from Patrick Donnelly with Citi. Your line is open.
Speaker Change: Hey, guys. Thanks for taking my questions.
Speaker Change: Jim you talked a little bit about some of the trends in the DSA bookings side.
Speaker Change: Nice to see the book to Bill over one.
Speaker Change: A couple of years.
Speaker Change: I guess now that it's over one and the expectation that it kind of stays here I know you guys don't guide quarterly book to Bill, but what's the sense.
Speaker Change: It sounds again, I, just want to remain a little bit cautious with with what's going on in the backdrop.
Speaker Change: How do you think about just the book to Bill trends going forward, given what youre seeing on the bookings environment in your customer conversations.
Speaker Change: Thanks, Phil.
Okay.
Speaker Change: Okay.
Speaker Change: Anxiously awaiting.
Speaker Change: We're also be.
Speaker Change: We saw some good luck.
Speaker Change: Okay.
Speaker Change: With one quarter.
Speaker Change: Quarter.
Speaker Change: You have to see.
Speaker Change: Okay.
Speaker Change: Rob.
Speaker Change: Sure.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Okay.
Okay, and then Flavio, maybe just okay, sorry, Jim.
Speaker Change: Go ahead.
Speaker Change: Alright.
Speaker Change: Go ahead Patrick.
Speaker Change: Yes, sorry, just on the on the margins.
Speaker Change: Okay.
Speaker Change: I think previously you guys were talking about DSA.
Speaker Change: This year.
Speaker Change: So just moving pieces.
Speaker Change: Okay.
Speaker Change: On the right way to think about the go forward. Thank you.
Speaker Change: Yes, I think.
Speaker Change: Okay.
Speaker Change: We encourage that.
Speaker Change: Formats in the first quarter.
Speaker Change: Got it.
Speaker Change: With a strong.
Speaker Change: Performance.
Speaker Change: As I said.
Speaker Change: Jim just said, we're being cautious in the second half.
Speaker Change: Yes.
Speaker Change: On the other hand.
Speaker Change: We still predict on manufacturing.
Speaker Change: Okay.
Speaker Change: Throughout the year.
Speaker Change: Notable items in the first quarter.
Speaker Change: Given the headwinds from Cvs.
Speaker Change: As well with <unk>.
Speaker Change: Relative basis, a little slower start.
Speaker Change: <unk> disgusting.
Speaker Change: Okay.
Speaker Change: Do you think about the margin.
Speaker Change: I think we.
Speaker Change: It took all of you guys as employees.
Try to finesse for you a little bit and provide specificity on the margin.
Speaker Change: Got it.
Speaker Change: Minus 22, minus 50 bps versus last year as opposed to modestly still consistent with the prior guidance. We just tried to define it for you a little bit.
Speaker Change: But overall we're.
Speaker Change: Pleased with.
Speaker Change: Cost saving efforts.
Speaker Change: We put in place over the last 18.
Speaker Change: 18 months to help protect the operating margin.
Speaker Change: In the face.
Speaker Change: Gotcha.
Speaker Change: We're going to continue to work hard too.
Speaker Change: Can enhance margin as much as possible.
Speaker Change: Okay. Thank you guys.
Speaker Change: Thank you our next question comes.
Speaker Change: Casey Woodring with J P. Morgan.
Speaker Change: Your line is open.
Speaker Change: Great. Thank you for taking my questions.
Speaker Change: I'm curious what your updated expectations are for biotech.
Speaker Change: This year, just given the weaker funding numbers to start the year I think you said revenue for biotech clients grew in the quarter and it seems like the cancellations declines, but you said gross bookings really led by large pharma. So just curious Patrick.
Speaker Change: Look here and then a large pharma how are you.
Speaker Change: Conversations going with these customers on potential tariffs and maybe just thank.
Speaker Change: Thank you.
Speaker Change: Sure. Thank you.
Speaker Change: Yes so.
Speaker Change: On the second part of your question Jason.
Speaker Change: Okay.
Speaker Change: Obviously, we continue to monitor the news like everybody else.
Speaker Change: Okay.
Speaker Change: Just yesterday again I think the sector was pressured.
Speaker Change: Hum.
Vacation that makes sense.
Speaker Change: Back on the.
Speaker Change: On the table.
Speaker Change: I think.
Speaker Change: In terms of how that is translating to dialog and activity with our.
Speaker Change: From our clients.
Speaker Change: Nothing in particular.
Speaker Change: Necessarily impact.
Speaker Change: Their R&D dollars as of now.
Speaker Change: We will continue to.
Speaker Change: Monitor that.
Speaker Change: Hope that.
Speaker Change: I would say good sense prevails in the tariffs.
Speaker Change: Not implemented, but we obviously can't control that.
Speaker Change: Paris impact directly to our business.
Speaker Change: I said in my prepared remarks.
Speaker Change: It's very modest in that small impact.
Speaker Change: Jim.
Speaker Change: Okay.
Speaker Change: Does that trend.
Speaker Change: Pharma.
Speaker Change: Yes.
Speaker Change: It's tough to predict.
Speaker Change: Funding situation is improving for biotech so.
Speaker Change: We would anticipate any symptoms.
Speaker Change: Change.
Speaker Change: And the demand from them.
Speaker Change: They can't do everything.
Speaker Change: Okay.
Speaker Change: Get as many drugs into the clinic as possible so.
Speaker Change: Part of that.
Speaker Change: Our client base.
Speaker Change: Yeah.
Speaker Change: I think the clients.
Speaker Change: Yes.
Speaker Change: High quality science, and some regulatory expertise will continue.
Speaker Change: Okay.
Speaker Change: Primarily used Charles River.
Speaker Change: Really well for us.
Speaker Change: And where we are.
Speaker Change: Being very thoughtful about the way we're pricing.
Speaker Change: Pricing studies so.
Speaker Change: Okay.
Speaker Change: We didn't anticipate.
Speaker Change: Yes.
Speaker Change: Thank you our next question.
Charles: Comes from Charles <unk> with TD Cowen Your line is open.
Charles: Yes, thanks, Thanks for taking my questions.
Speaker Change: Questions.
Speaker Change: Maybe wanted to ask about TSA did a slightly different way.
Speaker Change: Obviously, you mentioned earlier that Youre seeing.
Speaker Change: Please go ahead.
Speaker Change: <unk> decline here.
Speaker Change: Can you talk about sort of risks.
Speaker Change: You.
Speaker Change: Cancellations, maybe ticking back up.
Speaker Change: Given the short time cycles and the quick study starts.
Speaker Change: It would seem that that's a much lower risk than it has been in the past.
Speaker Change: Secondly.
Speaker Change: Unfortunately.
Speaker Change: <unk> from <unk>.
Speaker Change: <unk> three would be helpful. Thanks.
Speaker Change: Cancellation rates.
Speaker Change: Cancellations are always part of our business.
Speaker Change: For years, we will continue to be.
Speaker Change: And so.
Speaker Change: Yes.
Speaker Change: The normal pattern.
Speaker Change: Okay.
Speaker Change: And changes.
Speaker Change: Priorities.
Speaker Change: So we sort of build that into our business.
Speaker Change: That's why we'd like to have meaningful backlog slide.
Speaker Change: As a penalty for cancellations by the way.
Speaker Change: Cancellations have been coming down nicely for a while now.
Speaker Change: Over a year.
Speaker Change: We have target levels is really an important indication.
Bill: This is bill.
Speaker Change: The demand point of view in the market.
Karl crews: This is Karl again.
Bill: Obviously.
Bill: First quarter. This decline was much less than we had guided to an aunt.
Bill: <unk>.
Bill: Fair amount of work out their SaaS studies time, it's much more complex expensive studies.
Bill: Since the backlog sufficient.
Bill: We have an elongated.
Bill: Okay.
Bill: Studies associated with them.
Bill: With slots.
Bill: We don't see the cancellation rate that we saw.
Bill: We had a backlog of caught up to it.
Speaker Change: I think 18 months clients.
Bill: And then at that point consumer safety.
Bill: Not having a corresponding studies. So I think we're past all of that is much more measured thoughtful approach.
Bill: Again.
Bill: Okay.
Bill: Cancellation rates continue to come down and that's definitely a positive for us.
Bill: <unk>.
Bill: The FDA.
Bill: No.
Bill: Okay.
Bill: The second part of my question.
Yes.
Bill: Yes.
Bill: Have had the FTAA.
Bill: One of our commercial clients.
Bill: We have been working really closely with the FDA back and forth.
Bill: To respond to the request.
Bill: Yeah.
Bill: They wanted more information.
Bill: I think thats going very well.
Bill: <unk> continues to give us confidence if and when clients move into a commercial.
Bill: Okay.
Bill: This will be in good shape to accommodate.
Bill: Great. Thank you.
Bill: Yeah.
Bill: Thank you. Our next question comes from Tejas Savant.
Speaker Change: Good morning Stanley Your line is open.
Speaker Change: Hey, guys.
Bill: Morning, and thanks for the time here.
Bill: Yes.
Bill: But I do have a couple of clean ups on on the FDA animal testing is done.
Bill: Action of ma'am.
Bill: Typically require these chronic <unk> studies and what traction were getting in FTE Wheeler and secondly, just in terms of some of the early conversation.
Bill: You may have had with your customers.
Bill: Is there a scenario in which pharma might prefer to run animal studies anyway.
Bill: Make sure we don't see a spike in phase one or two failures in human driver.
Bill: Yeah.
Bill: Yes so.
Bill: Does that.
Bill: Continue to use them.
Bill: Methodology that ensures patient safety and so as we said in our prepared remarks.
Bill: Yes.
Bill: Okay substitute for wholly owned systems right now you have this little narrow niche right now which is longer term.
Bill: Monoclonal antibody studies for.
Bill: Chronic studies.
Bill: And.
Bill: Its determination is.
Bill: To elongate.
Bill: That's a thoughtful thing to do.
Bill: <unk>.
Bill: And as we said in the prepared remarks.
Bill: For a period of time.
Bill: So this pilot study will.
Bill: We will probably prove itself.
Speaker Change: Thanks, Paul portion.
Bill: Yes, it's about $50 million.
Bill: Our business.
Bill: Thats tied up in these longer term chronic and hp's monoclonal.
Bill: Ed.
Bill: Other large molecule.
Bill: Sure.
Bill: Okay.
Bill: Fundamental demands.
Bill: Technology.
Bill: Yes.
Bill: So in addition to.
Bill: Assuming that evercore.
Bill: So this will be.
Bill: Okay.
Bill: Yeah.
Bill: Yeah.
Bill: So the FDA has given the draft.
Bill: Permission to utilize more of these.
Bill: But.
Bill: They.
Bill: Hey will.
Bill: The responsibility upon us sure.
Bill: So regardless of what the regulatory agencies.
Bill: Science works right.
Bill: And that's why we think that hybrid approaches.
Bill: As we go forward will be beneficial.
Bill: Okay.
Bill: Yes sure.
Bill: Questions.
Bill: When youre looking at a whole body.
Bill: Applications, you have a whole animal system.
Bill: Combined.
Bill: We're pretty confident.
Bill: The extent to which technology develops in the future.
There could be some sort of substitute.
Bill: It's possible.
Bill: Certainly.
Bill: Elevation.
Bill: Acceptance and validation by the radio.
Bill: <unk> will be important to understanding of all of this.
Speaker Change: As we said earlier, we will have a substantial role.
Bill: And leading that and helping our clients.
Bill: At that point, where theyre comfortable with traditional technologies.
Bill: Okay.
Bill: Okay. That's helpful. And then just a quick follow up on on the strategic review.
Bill: Thinking about it.
Bill: Okay.
Bill: <unk> relatively quick turnaround, but can we expect an update by the time of the next earnings call for example, or perhaps even sooner.
Speaker Change: And then one for Flavio you've done.
Bill: Yeah.
Bill: A pretty good job with Costco up here I think 5% of over 5% of your cost structure has been eliminated.
Bill: In the context of the strategic review or further cost Scott kind of thing.
Bill: Lower priority item in your view given how much work you've already done there and obviously you don't want to impair your ability to lead into an eventual robust market recovery.
Bill: I'll take the first part so the strategic review.
Bill: Yes.
Bill: We haven't started yet.
Bill: Okay.
Bill: Elliot.
Bill: That committee is going to meet often I don't know exactly what the cadence is yes.
Bill: And we're going to go really deep.
Speaker Change: As I said earlier markets wondering what's the competitive dynamic has the technology is developing.
Bill: And we gain the returns.
Speaker Change: Our acquisitions that we wanted.
Bill: What's the margin profile look like.
Speaker Change: We continue to win.
Bill: Portfolio.
Bill: So.
Bill: Got it takes some time, so I don't know exactly what will happen.
Bill: Move through it swiftly.
Bill: So without <unk>.
Bill: Yeah.
Bill: We will have.
Bill: By the next earnings call.
Bill: Yeah, and I think just.
Speaker Change: Thank you you pointed out we are pleased.
With the actions taken so far.
Speaker Change: They were necessary obviously given.
Speaker Change: The demand in March.
Speaker Change: But as I talked.
Speaker Change: Sure.
Speaker Change: The earnings earnings call some of those.
Speaker Change: The savings that we have identified.
Speaker Change: They are not good.
Speaker Change: I have to add back staffing.
Speaker Change: For about $75 million of the 225, and so I think well.
Speaker Change: Well.
Speaker Change: Continue to take a look at opportunities to always be efficient.
Speaker Change: To your point I think we've done a lot on this space already and so.
Speaker Change: We'll update you on the strategic review.
Speaker Change: That's completed.
Speaker Change: Fair enough. Thank you so much guys I appreciate it.
Speaker Change: Thank you our next question.
Speaker Change: Mac Sykes with Goldman Sachs. Your line is open.
Speaker Change: Good morning. Thank you for taking our question will on for Matt here, a lot's been asked so I'll keep it to one but within DSA.
Speaker Change: What's the demand environment different between safety assessment and discovery work it sounds like the discovery or earlier stage work was a little weaker but just wanted to unpack that.
<unk>.
Speaker Change: Discovery was weak.
Speaker Change: And we're doing that.
Speaker Change: Yes.
Speaker Change: Sure.
Speaker Change: Combined sales force.
Speaker Change: Across discovery, all the way through safety.
Speaker Change: So we are much more integrated approach.
Speaker Change: We're optimistic.
Speaker Change: Yes.
Speaker Change: With our discovery clients, having said that.
Speaker Change: Hi.
Speaker Change: So you can see.
Speaker Change: Larger drug companies.
Dollar wise.
Speaker Change: Haven't swung back significant amounts of investments in discovery.
Speaker Change: And again.
Speaker Change: These file and get this post sandy work into the clinic and obviously.
Speaker Change: At the end of the marketplace.
Speaker Change: Six pending.
Speaker Change: Okay.
Speaker Change: Patent curve so at some point.
Speaker Change: Pendulum will swing back.
Speaker Change: Got it.
Speaker Change: Absolutely discovery, they're going to have really last few portfolios going forward.
Speaker Change: Hi, guys.
Speaker Change: Okay.
Speaker Change: Quarter discovery hopefully the.
Speaker Change: Enhanced sales focus will improve that.
Speaker Change: We will let you know.
Speaker Change: Got it thanks for all the color guys.
Speaker Change: Thank you. Our next question comes from Scott <unk> with Barclays. Your line is open.
Speaker Change: Your line is open.
Speaker Change: Check yourself mute.
Speaker Change: Hearing no response, we'll move to our next.
Josh Waldman: Our next question comes from Josh Waldman with Cleveland Research. Your line is open.
Speaker Change: Hey, good morning, Thanks for taking our questions. This is Robert control.
Speaker Change: I wanted to come back to biotech, where you mentioned salesforce.
Speaker Change: Biotechs grew for the second consecutive quarter despite funding challenges.
Speaker Change: Okay.
Speaker Change: All three segments and then any differences to call out in terms of midsize biotech versus small biotech. Thank you.
Speaker Change: Yes.
Speaker Change: We don't distill that finitely between small and large biotech.
Speaker Change: We just try to provide color, but in terms of large pharma and biotech so to your point for the second consecutive quarter, we saw growth there which was encouraging.
Speaker Change: Okay.
Speaker Change: Thanks, Greg.
Speaker Change: We have no further questions at this time I will turn the call back over to Todd Spencer for closing remarks.
Speaker Change: Great. Thank you. Thank you for joining us on our conference call. This morning, we look forward to seeing you at upcoming Investor conferences. This concludes the conference call. Thank you.
Speaker Change: Thank you. This does conclude today's program.
Speaker Change: For laboratories.
Speaker Change: 2025 earnings Conference call. Thank you for your participation you may now disconnect.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Oh no no.
Speaker Change: Mhm.
Oh.
Speaker Change: [music].
Speaker Change: Hum.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Yeah.
Speaker Change: Hum.
Speaker Change: Okay.
Speaker Change: [music].